Quantum Biopharma highlights unbuzzd trial results

Executive Summary

• Quantum Biopharma Ltd. announced the peer-reviewed publication of a double-blind, randomized, placebo-controlled clinical trial for its dietary supplement, Unbuzzd, demonstrating significant efficacy in accelerating alcohol metabolism and reducing intoxication symptoms.
• The trial results indicate that Unbuzzd reduces blood alcohol concentration (BAC) more than 40% faster than placebo within the first 30 minutes, while also improving alertness, stabilizing vital signs, and reducing hangover severity.
• Quantum Biopharma retains a 19.86% ownership stake in Unbuzzd Wellness Inc. and is entitled to a 7% royalty on sales until $250 million is reached, after which the rate drops to 3% in perpetuity.

Key Details

• Trial Design: Double-blind, randomized, placebo-controlled crossover design (NCT06505239), published in the World Journal of Pharmaceutical and Medical Research (2026, Vol 12, Issue 3, pp. 446-467).
• Study Population: Healthy male and female participants aged 21–43, weighing 119–232 lbs.
• Protocol: Participants consumed alcohol to achieve a BAC of 0.07%–0.11%, followed by ingestion of Unbuzzd or placebo. BAC, vital signs, and intoxication symptoms were monitored.
• Metabolism Results: Unbuzzd accelerated the rate of BAC reduction by an average of more than 40% within the first 30 minutes compared to placebo. This acceleration was statistically significant and observed in both males and females over a four-hour period.
• Alertness and Cognition: Participants reported statistically significant improvements in alertness and fewer cognitive errors within 30 minutes of consuming Unbuzzd.
• Physiologic Changes: Unbuzzd significantly lessened the elevation in heart rate and drop in blood pressure associated with intoxication, stabilizing both metrics.
• Hangover Relief: Statistically significant reduction in hangover symptoms, including a 67% reduction in headache severity at four hours and continued relief at eight hours post-consumption.
• Safety Profile: The product was well-tolerated with no reported adverse side effects.
• Corporate Structure & Royalties:
  • Quantum Biopharma owns 19.86% of Unbuzzd Wellness Inc. (as of Sept 30, 2025).
  • Royalty structure: 7% of sales until $250 million is paid, then 3% in perpetuity.
  • Quantum retains 100% of rights to develop similar products for pharmaceutical/medical uses.
  • Quantum holds approximately $130 million in tax loss carry-forwards.

Notable Quotes

• "The unbuzzd clinical trial has now been published in a peer-reviewed international journal, and the trial confirms the exceptional overall efficacy of unbuzzd to help reduce the acute effects of alcohol intoxication and hangover, all without causing adverse side effects," said Dr. Andrzej Chruscinski, vice-president of clinical and scientific affairs at Quantum Biopharma.
• "This publication validates unbuzzd as a responsible aid to reduce BAC, alleviate signs of alcohol intoxication and assists with the dreaded hangover. Consumers can use unbuzzd knowing there is a peer-reviewed scientific publication with clinical trial evidence of the product's efficacy." — Anthony Durkacz, founder and executive co-chairman of Quantum Biopharma.